ArticleEuropean journal of nuclear medicine and molecular imaging2021
2-[
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 44 citations in OpenAlex.
- [European journal of nuclear medicine and molecular imaging · 2026Trial
- CAIX-targeted PET/CT in the evaluation of clear cell renal cell carcinoma: a head-to-head comparison with [European journal of nuclear medicine and molecular imaging · 2026Trial
- HER2-targeted PET/CT imaging provides potential biomarkers for differentiating HER2-zero, -low, and -positive breast cancer.European journal of nuclear medicine and molecular imaging · 2025Trial
- Diagnostic efficacy of [European journal of nuclear medicine and molecular imaging · 2024Trial
- Toward a Structured Imaging Reporting System for Kidney Masses: The Molecular Imaging Perspective on KI-RADS.Molecular imaging and biology · 2026Review
- 18 F-FDG PETCT in a Patient With Succinate Dehydrogenase-Deficient Renal Cell Carcinoma.Clinical nuclear medicine · 2026Article
- Article
- Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types usingEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Role ofJapanese journal of radiology · 2025Review
- Molecular imaging of renal cell carcinomas: ready for prime time.Nature reviews. Urology · 2025Review
- Diagnostic and prognostic role ofEJNMMI research · 2025Article
- Comparative analysis of metabolic characteristics and prognostic stratification of HER2-low and HER2-zero breast cancer usingCancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- The value of radiomics based on 2-[18 F]FDG PET/CT in predicting WHO/ISUP grade of clear cell renal cell carcinoma.EJNMMI research · 2024Article
- Ultrasound contrast-enhanced radiomics model for preoperative prediction of the tumor grade of clear cell renal cell carcinoma: an exploratory study.BMC medical imaging · 2024Article
- Nomogram combining pre-operative clinical characteristics and spectral CT parameters for predicting the WHO/ISUP pathological grading in clear cell renal cell carcinoma.Abdominal radiology (New York) · 2024Article
- A tumor-like renal arteriovenous malformation onFrontiers in medicine · 2024Article
- A multi-model based on radiogenomics and deep learning techniques associated with histological grade and survival in clear cell renal cell carcinoma.Insights into imaging · 2023Article
- Technologic advances in robot-assisted nephron sparing surgery: a narrative review.Translational andrology and urology · 2023Review
- WHO/ISUP grade and pathological T stage of clear cell renal cell carcinoma: value of ZOOMit diffusion kurtosis imaging and chemical exchange saturation transfer imaging.European radiology · 2023Article
- Head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo explore the potential parameters from preoperative 2-[
methodsOne hundred twenty-five patients with newly diagnosed ccRCC who underwent 2-[
resultsMetabolic parameters of primary tumor maximum standardized uptake value (SUVmax), tumor-to-liver SUV ratio (TLR), and tumor-to-kidney SUV ratio (TKR) were significantly different between any two of the four different WHO/ISUP grades, except those between the WHO/ISUP grade 3 and grade 4. The optimal cutoff values to predict high WHO/ISUP grade for SUVmax, TLR, and TKR were 4.15, 1.63, and 1.59, respectively. TLR (AUC: 0.841) was superior to TKR (AUC: 0.810) in distinguishing high and low WHO/ISUP grades (P = 0.0042). In univariate analysis, SUVmax, TLR, TKR, primary tumor size, tumor thrombus, distant metastases, and clinical symptoms could discriminate between the high and low WHO/ISUP grades (P < 0.05). In multivariate analysis, TLR (P < 0.001; OR: 1.732; 95%CI: 1.289-2.328) and tumor thrombus (P < 0.001; OR: 6.199; 95%CI: 2.499-15.375) were significant factors for differentiating WHO/ISUP grades.
conclusionElevated TLR (> 1.63) and presence of tumor thrombus from preoperative 2-[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.